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 Abstract. Phosphoinositol (PhoIns)-specific phospholipase C
enzymes (PLCs) are central to the inositol lipid signaling
pathways and contribute to intracellular Ca2+ release and
protein kinase C activation. Five distinct classes of PhoIns-
specific PLCs are known to exist in mammals, which are
activated by membrane receptor-mediated events. Here we
have identified a sixth class of PhoIns-specific PLC with a
novel domain structure, which we have termed PLC-Ë. Two
putative PLC-Ë enzymes were identified in humans and in
mice. Sequence analysis revealed that residues implicated in
substrate binding and catalysis from other PhoIns-specific
PLCs are conserved in the novel enzymes. PLC-Ë enzymes
are most closely related to the PLC-‰ class and share a close
evolutionary relationship with other PLC isozymes. EST
analysis and RT-PCR data suggest that PLC-Ë enzymes are
expressed in several cell types and, by analogy with other
mammalian PhoIns-specific PLCs, are likely to be involved
in signal transduction pathways.
Introduction
Phospholipase C enzymes (PLCs, EC 3.1.4.3) catalyze the
cleavage of membrane phospholipids to 1,2-diacylglycerol
(DAG) and their respective phosphoryl compound. In
mammals, five distinct classes of PLCs have previously been
identified (ß, Á, ‰, Â and ˙), all of which specifically react
with phosphoinositols (PhoIns) (1-3). PLC-cleavage of
phosphatidylinositol (PtdIns) 4,5-bisphosphate results in the
generation of DAG and inositol 1,4,5-triphosphate, which
promote the activation of protein kinase C and the release of
Ca2+ from intracellular stores, respectively (4,5). The five
known classes of mammalian PLCs contain several conserved
domains, which include Pleckstrin homology (PH), EF-hand,
catalytic X and Y and C2 domains. The enzymes have been
classified on the basis of amino acid sequence and by the
mechanisms they activate in response to ligand interactions
with various receptors. 
PLC-ß isozymes are activated by the action of G proteins
associated with plasma and nuclear membranes (6). G proteins
consist of ·, ß and Á subunits that are stably bound in the
inactive, GDP-bound state. Interface between the G protein
and an agonist-occupied receptor triggers the exchange of
GDP for GTP on the · subunit and its dissociation from the ß
and Á subunits. Both the G· subunit and GßÁ dimer activate
PLC-ß (7,8). PLC-Á isozymes are activated by the action of a
range of receptor protein tyrosine kinases, which auto-
phosphorylate upon binding of various growth factors (9).
These phosphorylation sites then function as docking sites
for PLC-Á (10). The mechanisms of PLC-‰ activation remain
poorly understood. PLC-‰ isozymes are more sensitive to
Ca2+ than other isozymes and may therefore be sufficient to
trigger their activation (1). Another potential regulator of
PLC-‰ enzymes is a recently discovered high-molecular-weight
G protein (11). This protein forms a complex with PLC-‰1 in
cells stimulated through ·1-adrenergic or oxytocin receptors
(11,12). The PLC-Â isozymes are involved in Ras signaling.
The Ras family of enzymes is a group of GTPases that
regulate pathways involved in cell proliferation, differentiation
and apoptosis (13). Expression of wild-type PLC-Â has been
shown to promote the generation of the GTP-bound form of
Ras in cultured cells (14,15). The last known member of the
mammalian PLC family, PLC-˙, has been identified as the
main trigger of Ca2+ oscillations at the very first stage of
development, when sperm meets egg (2). PLC-‰1 also induces
Ca2+ oscillations in eggs, albeit less efficiently than PLC-˙
(~20-fold higher concentration of PLC-‰1 is required) (16).
This suggests that PLC-˙ may be activated by a similar
mechanism to PLC-‰ isozymes.
PLCs that show specificity toward membrane phospholipids
other than PtdIns are present in bacteria (17) and are thought
to also exist in mammals. A role in mammalian signal
transduction for a phosphocholine (PhoCho)-specific PLC
has previously been described (18,19). These studies suggest
the existence of other mammalian PLC enzymes. Whilst
searching for a mammalian PhoCho-specific PLC, two new
PhoIns-specific PLC enzymes were identified. These enzymes,
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which we have named PLC-Ë1 and PLC-Ë2, are described
here.
Materials and methods
Database and sequence analysis. Searches were performed
using the Ensembl Genome Browser available from the
EMBL and Sanger Institute and with the tBLASTn algorithm
(NCBI) (20) using short stretches of sequence (20-30
amino acids) from phosphatidylcholine-specific PLC from
Pseudomonas fluorescens (accession no. AJ304443) (17).
The Pfam database (available from the Sanger Institute) (21)
was used to search for conserved PLC-associated domains in
resultant sequences. 
Phylogenic analysis. Initial multiple alignments of protein
sequences were carried out using the EMBOSS program,
EMMA (available from http://www.hgmp.mrc.ac.uk/
Registered/Option/emboss.html). A phylogenic tree was then
created from an aligned region (between 141 and 148 amino
acids long) using PHYLIP v3.6 (http://evolution.genetics.
washington.edu/phylip.html). One hundred bootstrap
replicates were initially used to run the analysis. The Jones-
Taylor-Thornton matrix (22) was then applied to the 100
datasets. A consensus of these datasets was found to give a
statistically significant tree with bootstrap values by the
Neighbour Joining method (23). The following sequences
were used (the hs- and mm- prefixes indicate human and
murine forms of the proteins, respectively; accession numbers
are shown in parentheses): hsPLC-ß1 (Q9NQ66), mmPLC-ß1
(Q9Z1B3), hsPLC-ß2 (NP_04564), hsPLC-ß3 (NP_000923),
mmPLC-ß3 (NP_032900), hsPLC-ß4 (NP_000924),
mmPLC-ß4 (NP_038857), hsPLC-Á1 (NP_002651),
mmPLC-Á1 (AAH65091), hsPLC-Á2 (P16885), mmPLC-Á2
(NP_758489), hsPLC-‰1 (Q8RB31), mmPLC-‰1 (Q8R3B1),
hsPLC-‰3 (NP_588614), mmPLC-‰3 (NP_690023), hsPLC-‰4
(NP_116115), mmPLC-‰4 (NP_683739), hsPLC-Â, 2303
amino acids form (AAG17145), hsPLC-Â, 1994 amino acids
form (AAG28341), mmPLC-Â (NP_062534), hsPLC-˙
(NP_149114), mmPLC-˙ (NP_473407), hsPLC-Ë1
(XP_042635), mmPLC-Ë1 (ENSMUSP00000047693; mouse
NCBIm32), hsPLC-Ë2 (XP_371214), mmPLC-Ë2 (ENSMUSP
00000030929; mouse NCBIm30), hsPLC-‰1 (P51178).
Semi-quantitative RT-PCR. Total RNAs were extracted from
various tissues of male DF1 mice, aged 3-4 weeks, by
phenol/chloroform extraction and treated with DNase I
(Ambion) according to the manufacturer's instructions. The
RT-PCR reaction was carried out using the Qiagen one-step
RT-PCR kit. Primer pairs for 18S RNA were used as a
control. The reaction mixture contained 100 ng RNA (25 ng
was used with 18S RNA primers), 0.6 µM primer pairs and
400 µM dNTPs. The oligonucleotide primers used were
PLC-Ë1: 5'-GAAAGATGCATGAGTGTAATGC-3' and 5'-
CTGAAACATTTGCCTGACTTTTC-3'; PLC-Ë2: 5'-
CCATCGACTCCATCCAGG-3' and 5'-TCCAGAAAGCGC
TGCAGG-3'. These primers sets were designed to span at
least one intron so that any amplification from contaminating
genomic DNA would be identified. Oligonucleotide primers
for 18S RNA were obtained from Ambion. The tissue RNAs
were reverse transcribed for 30 min at 50˚C, then murine
PLC-Ë1 and PLC-Ë2 transcripts were amplified using the
cycling profile: 30 sec at 94˚C (1st cycle 15 min at 95˚C);
30 sec at 57˚C; 1 min at 72˚C with 30 cycles. Each reaction
(12 µl) was analyzed on 1.5% agarose gels run in the
presence of ethidium bromide (250 µg/l).
Results and Discussion
Identification of novel PLC enzymes. A search of the human
EST database (NCBI) with sequence segments from PhoCho-
specific PLC from Pseudomonas fluorescens identified two
novel genes encoding predicted PhoIns-specific PLCs. The
corresponding proteins share 74% homology and are most
closely related to the PLC-‰ class of enzymes, with which
they share ~35% identity. A search within the Pfam database
revealed that both enzymes have a novel domain structure
containing PH, EF-hand, catalytic X and Y and C2 domains.
The two novel enzymes were named PLC-Ë1 and PLC-Ë2 in
accordance with current nomenclature. Fig. 1 shows the
domain organization within all known mammalian PhoIns-
specific PLC isozymes.
The PH domain (absent in PLC-˙) is a module found in
many signaling proteins that binds to polyphosphoinositides
(24) and indeed, many proteins that contain this domain
associate with phospholipid membranes (25,26). However, it
has recently been shown that the PH domain of PLC-‰4 is not
essential for membrane localization (27). The C-terminal
regions of several PH domains bind to the ßÁ subunits of G
proteins (28,29). The role of the EF-hand domain in PLCs is
unclear, but appears to serve as a flexible link between the
PH and the catalytic domains (30). The active site in PLCs
consists of both X and Y domains and requires Ca2+ for
catalytic function. The X domain is involved in both substrate
and Ca2+ binding, while the Y domain primarily interacts
with the substrate (30). It is these regions that contain the
highest degree of sequence similarity among different
mammalian PLCs (31). The C2 domain is essential for
catalytic activity (32) and often associated with proteins that
interact with phospholipids. In some PLCs, the C2 domain
binds Ca2+ and mediates Ca2+-dependent interactions with the
lipid membrane. It has been speculated that the C2 domain of
PLC-‰1 may contain as many as four Ca2+-binding sites (32).
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Figure 1. Domain organization in mammalian PhoIns-specific PLC-isozymes.
PH, Pleckstrin homology domain; EF, EF-hand domain; X, catalytic X
domain; Y, catalytic Y domain, C2, C2 domain; RasGEF, guanine nucleotide
exchange factor domain for Ras-like small GTPases; RA, Ras association
domain; SH, Src homology domain.
The presence of these sequence motifs in PLC-Ë enzymes
suggests they may also be involved in signal transduction. In
addition to these domains, several PLC isozymes contain
other sequence motifs that contribute to their activation.
PLC-Á isozymes contain SH2 and SH3 domains between the
catalytic X and Y domains, which facilitate their interaction
with receptor tyrosine kinases (10). Whilst PLC-Â isozymes
contain RasGEF and RA domains at their N- and C-terminal
ends, respectively (1). 
The genes encoding human PLC-Ë1 and PLC-Ë2 are
located on chr.3q25.31 and chr.1p36.32, respectively.
Orthologuous proteins were also identified in mice, although
it was found that the murine PLC-Ë1 mRNA sequence
corresponds to a protein that is ~350 residues longer at the
C-terminal end than its human equivalent. Partial sequences
that also appear to be orthologous were found in other species
including rat, zebrafish (Danio rerio), puffer fish (Takifugu
rubripes) and nematode worm (Caenorhabditis elegans)
(data not shown).
The putative PLC-
 
Ë enzymes. Analysis of the full-length
human transcripts using the web-based program, SignalP v1.1
(33), predicts the absence of a signal peptide in either protein.
This suggests that both proteins are soluble cytoplasmic
enzymes. Sequence comparison between PLC-Ë1, PLC-Ë2 and
PLC-‰s reveal significant differences. A sequence alignment
of human and murine PLC-Ë isozymes with human PLC-‰1 is
shown in Fig. 2. The region between the X and Y catalytic
domains is ~100 residues longer in PLC-Ë enzymes. Also,
the human PLC-Ë isozymes contain an additional C-
terminal region that is particularly rich in serine and proline
residues. Serine- and proline-rich regions have been found in
many transcription factors and have a proposed role in protein-
protein interactions (34,35). This region may therefore have
functional importance in these enzymes.
The X-ray crystal structure of rat PLC-‰1 in the presence
of bound calcium and inositol 1,4,5-triphosphate reveal that
residues His311, Asn312, Glu341, Asp343, and Glu390
coordinate to the catalytic Ca2+ ion. In addition, Lys438,
Lys440, Ser522, Arg549 and Tyr551 are shown to specifically
interact with inositol 1,4,5-triphosphate (12). This is supported
by mutational analysis, which confirm that Asn312, Glu341,
Asp343 and Glu390 contribute toward Ca2+-binding and
demonstrate Lys438, Ser522 and Arg549 to be important for
the preferential hydrolysis of polyphosphoinositides (36). All
of the aforementioned PLC-‰1 residues known to be involved
in substrate binding and catalysis are completely conserved
within the catalytic X and Y domains of PLC-Ë1 and PLC-Ë2
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  15:  117-121,  2005 119
Figure 2. Sequence alignment of human and murine PLC-Ë enzymes with human PLC-‰1. Conserved and semi-conserved residues implicated in substrate and
Ca2+ binding are highlighted (conserved, black boxes; semi-conserved, grey boxes). The following sequences are used (accession numbers are shown in
parentheses): HSPLCË1, human PLC-Ë1 (XP_042635); MMPLCË1, murine PLC-Ë1 (ENSMUSP00000047693); HSPLCË2, human PLC-Ë2 (XP_371214);
MMPLCË2, murine PLC-Ë2 (ENSMUSP00000030929); HSPLC‰1, human PLC-‰1 (P51178).
(Fig. 2). As a result, it is very likely that the PLC-Ë enzymes
also function as PhoIns-specific phospholipases in vivo.
The Ca2+-mediated lipid-binding site in the C2 domain of
synaptotagmin I consists of four aspartate residues, Asp172,
Asp178, Asp230 and Asp232 (37). All four of these residues
are conserved in the PLC-Ë enzymes, but not in PLC-‰1
where Asp172 is equivalent to Asn645 (12). This suggests
that Ca2+ ions bind more tightly at this site to synaptotagmin I
and to the PLC-Ë enzymes than to PLC-‰1. Additionally, it
indicates that PLC-Ë enzymes, like other PLCs, interact with
membrane lipids following Ca2+ binding at this region. Other
groups of PhoIns-specific PLCs such as the PLC-ß and PLC-Á
enzymes also contain a C2 domain, yet key residues involved
in Ca2+ binding are not conserved (3). This is a similar
situation to that observed within some protein kinase C and
synaptotagmin subtypes whose C2 domains are also unable
to bind calcium. It has been speculated that within these
enzymes the function of the C2 domain is to recognize other
regulatory lipids or proteins. For example, the C2 domain of
PLC-ß1 has been found to bind specifically to GTP-charged
·q, its physiological activator (38).
Phylogenic analysis performed with human and murine
PLC-Ë1 and PLC-Ë2 protein sequences reveal that a close
evolutionary relationship exists between these and other
PhoIns-specific PLC enzymes. Fig. 3 shows a rooted
phylogenic tree of human and murine PLCs with bootstrap
values inserted at each branch node. The tree reveals that PLC-Ë
isozymes lie closest to the root and supports the classification
of these novel enzymes into a new group. PtdIns-specific
PLC-Ë enzymes are consequently likely to have formed at an
earlier point during evolution than the other PLCs and may
exist in a wider range of species.
Tissue distribution of PLC-Ë enzymes. At present, ESTs
available in dbEST at the NCBI server indicate that the gene
encoding human PLC-Ë1 is expressed in colon, embryonic
stem cells, retinoblastoma and teratocarcinoma cells. ESTs
corresponding to human PLC-Ë2 were identified in cDNAs
isolated from anaplastic oligodendroglioma, epithelioid
carcinoma, leukopheresis, lymph, nerve tumor, optic nerve,
pancreatic islet, pituitary and retinoblastoma cell populations.
Murine ESTs corresponding to PLC-Ë1 were found in
cDNAs isolated from brain, eye, kidney, neural retina and
upper head. The murine PLC-Ë2 sequence matched ESTs
from brain. RT-PCR analysis of RNA isolated from a range
of murine tissues revealed bands of expected size
corresponding to the expression of both PLC-Ë enzymes in
the brain and gut (Fig. 4). The observed expression of both
enzymes in the brain by RT-PCR is in agreement with the
EST data. No detectable expression was observed in the
other tissues assayed.
By analogy with other PhoIns-specific PLCs, these data
suggest that the PLC-Ë enzymes may function in the
membrane-mediated signaling cascade through intracellular
Ca2+ and protein kinase C pathways in several different cell
types. Such pathways are crucial for the initiation of cellular
processes including proliferation, differentiation and apoptosis.
The discovery of these enzymes is therefore important and is
expected to trigger further research towards their cellular
function.
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